Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00564161
First received: November 25, 2007
Last updated: November 26, 2007
Last verified: November 2007
  Purpose

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the CSF of preterm infants can be used as a biomarker to predict the risk for developming white matter damage.


Condition
Preterm Infants With White Matter Damage
Preterm Infants Developing Normally

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples Without DNA

CSF.


Estimated Enrollment: 40
Study Start Date: January 2008
Estimated Study Completion Date: January 2009

  Eligibility

Ages Eligible for Study:   25 Weeks to 40 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

preterm infants.

Criteria

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00564161

Contacts
Contact: Talya Dor, MD 972-50-8946-704 talyad@hadassah.org.il
Contact: Itai Berger, MD itberg@hadassah.org.il

Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Talya Dor, MD Hadassah Medical Organization
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00564161     History of Changes
Other Study ID Numbers: 606060-HMO-CTIL, 606060-HMO-CTIL
Study First Received: November 25, 2007
Last Updated: November 26, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

ClinicalTrials.gov processed this record on November 20, 2014